作者: Xuan Ren , Mei Dai , Li-Ping Lin , Pui-Kai Li , Jian Ding
DOI: 10.1111/J.1476-5381.2009.00112.X
关键词:
摘要: Background and purpose: The critical role of blood supply in the growth solid tumours makes vessels an ideal target for anti-tumour drug discovery. anti-angiogenic vascular disrupting activities C9, a newly synthesized microtubule-depolymerizing agent, were investigated with several vitro vivo models. Possible mechanisms involved its activity also assessed. Experimental approach: Microtubule-depolymerizing actions assessed by surface plasmon resonance binding, competitive inhibition cytoskeleton immunofluorescence. Anti-angiogenic tested on proliferation, migration, tube formation human umbilical vein endothelial cells, rat aortic ring, chick chorioallantoic membrane Matrigel plug assays. Western blots Rho activation assays employed to examine Raf-MEK-ERK (mitogen-activated ERK kinase, extracellular signal-regulated kinase) Rho/Rho kinase signalling. Key results: C9 inhibited migration cells angiogenesis ring induced disassembly microtubules down-regulated signalling activated pro-angiogenic factors. In addition, disrupted capillary-like networks formed rapidly decreased perfusion neovasculature vivo. Endothelial cell contraction blebbing was dependent pathway. Conclusions implications: disruption associated changes morphology function involving pathways. These findings strongly suggest that is new microtubule-binding agent could effectively tumour vasculature.